An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose is to assess the efficacy and safety of eculizumab in pediatric patients
with aHUS to control TMA as characterized by thrombocytopenia, hemolysis and renal
impairment.